Technology and Patents
About microRNAs and miR-7
miReven holds worldwide exclusive rights to the UWA miR-7 patents, creating a solid IP portfolio protecting the commercialisation of miR-7 as an anti-cancer therapeutic.
Our patent estate includes 4 patent families to date, 3 of which are published and have entered National Phase examination in multiple jurisdictions including the US and Europe.
|1||Method of Modulation of Expression of Epidermal Growth Factor Receptor (EGF-R) involving miRNA||US 8673872-Granted EP 2061482 - Granted||Method of use miR-7 cancer (EGFR-related)||Peter Leedman Keith Giles Rebecca Webster|
|2||Methods and compositions for increasing sensitivity to tyrosine kinase inhibitors||AU 2010324530 - Granted CA 2781572 - Pending US 9051551- Granted EU 2521555 - Granted||Methods and composition for miR-7 combination therapy||Peter Leedman Keith Giles Felicity Kalinowski|
|3||Cancer therapy using miRNAs||US 9795626 - Granted EU 13847499.4 – under examination IN 4209/DELNP/2015 - pending CH 201380065503.0 - pending||Methods of use miR-7 cancer (IGFR-related, melanoma)||Peter Leedman Keith Giles Rikki Brown|